We are excited to introduce TAP, the newest company to emerge from 8VC’s Build program. Read on to learn how TAP is partnering with industry leaders to teach the skills needed to thrive in the 21st century economy, while helping underserved communities to create opportunities and mentorship networks close to home.

In 2022, the technology sector experienced its biggest downturn in a generation, marking the end of a formidable bull run in Silicon Valley. Many are wondering what the downturn in tech equities means for venture capital as an asset class. Is VC better today than it was a few years ago? How does it compare to competing assets like the rest of private equity, public markets, cash, credit, etc?

We’re pleased to announce 8VC’s participation in the $75 million Series A for Photys Therapeutics, led by MPM Capital and joined by Omega Funds, Longwood, Arkin Bio, Mass General Brigham Ventures, MRL Ventures Fund, Eli Lilly and Company, and Heritage Medical Systems.